Basics |
Taysha Gene Therapies, Inc.
|
IPO Date: |
September 24, 2020 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$916.59M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.28 | 4.19%
|
Avg Daily Range (30 D): |
$0.07 | 2.28%
|
Avg Daily Range (90 D): |
$0.08 | 3.09%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.36M |
Avg Daily Volume (30 D): |
2.6M |
Avg Daily Volume (90 D): |
3.2M |
Trade Size |
Avg Trade Size (Sh.): |
207 |
Avg Trade Size (Sh.) (30 D): |
191 |
Avg Trade Size (Sh.) (90 D): |
199 |
Institutional Trades |
Total Inst.Trades: |
345 |
Avg Inst. Trade: |
$1.92M |
Avg Inst. Trade (30 D): |
$1.65M |
Avg Inst. Trade (90 D): |
$1.38M |
Avg Inst. Trade Volume: |
.63M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$2.64M |
Avg Closing Trade (30 D): |
$.84M |
Avg Closing Trade (90 D): |
$1.09M |
Avg Closing Volume: |
775.66K |
|
|
Financials |
|
TTM |
Q2 2025 |
Q1 2025 |
Basic EPS
|
$-.34
|
$-.09
|
$-.08
|
Diluted EPS
|
$-.34
|
$-.09
|
$-.08
|
Revenue
|
$ 8.1M
|
$ 1.99M
|
$ 2.3M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -92.72M
|
$ -26.88M
|
$ -21.53M
|
Operating Income / Loss
|
$ -94M
|
$ -26.75M
|
$ -21.42M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ 140.02M
|
$ 196.17M
|
$ -22.44M
|
PE Ratio
|
|
|
|
|
|
|